Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based. Read more…
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
Long-acting (LA) therapies represent a significant innovation in pharmaceutical development by offering a sustained drug effect with reduced administration frequency.
An Analysis of NICE’s Optimised Decisions from 2015 to 2024
1 May 2025
The National Institute for Health and Care Excellence (NICE) is the body responsible for recommending medicines for use within the National Health Service (NHS) in England.
The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region
14 April 2025
Health Technology Assessment (HTA) agencies evaluate and make decisions on the use, funding, or reimbursement of health technologies based on clinical and economic evidence.
Around the World in HTAs: Canada – Autonomous yet Collaborative
9 April 2025
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Adam Raymakers and Chris Skedgel take us to Canada.
Challenges and Solutions for Budget Impact Analysis of Gene Therapies
10 March 2025
Gene therapies represent a paradigm shift in medicine, offering the potential for significant improvements in both quality and longevity of life, by addressing the root genetic…
Infectious disease: another reason to try Veganuary for the NHS
30 January 2025
We dust off last year’s model to consider the potential savings to the NHS from more people going vegan, with a focus on COVID-19.
Is collaboration between and across regulatory and HTA agencies the answer to access challenges?
12 November 2024
More collaborative initiatives are taking place among regulatory agencies, health technology assessment (HTA) bodies and between regulatory and HTA agencies at national and regional levels.
Around The World in HTAs: Thailand – An Ever-Evolving Policy Tool
9 September 2024
In our Around the World in HTAs insight series we shed light on HTA successes and challenges around the world. In this edition, Sarin KC, Manit Sittimart, Chittawan Poonsiri, Yi Wang, and Simon Brassel take us to Thailand.
Unlocking the Value of Combination Therapies
9 July 2024
Combination therapies (CTs) merge treatments with different mechanisms of action to achieve greater clinical benefits than the individual components alone. CTs are increasingly being used in oncology.